Last reviewed · How we verify
NCT03651245: EUMAP
European Alpha-Mannosidosis Participant
trial in Immunodeficiency in 667 participants. Terminated before completion.
30 May 2022
Quick facts
| Lead sponsor | CENTOGENE GmbH Rostock |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 667 |
| Start date | 20 August 2018 |
| Primary completion | 30 May 2022 |
| Estimated completion | 30 May 2022 |
| Sites | 19 locations across Switzerland, Germany |
Conditions studied
- Immunodeficiency — all drugs for Immunodeficiency →
- Skeletal Abnormalities — all drugs for Skeletal Abnormalities →
- Deafness — all drugs for Deafness →
- Mental Retardation — all drugs for Mental Retardation →
Sponsor
CENTOGENE GmbH Rostock
Who can join
Adults 2 Months to 18, any sex, with Immunodeficiency or Skeletal Abnormalities. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
International, multicenter, observational, longitudinal monitoring study to investigate the prevalence of Alpha-Mannosidosis in participants at risk for Alpha-Mannosidosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03651245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunodeficiency
Currently open trials in the same condition.
- NCT06612515 — Vaccine-induced Immunity in Immunocompromised Patients · recruiting
- NCT06248957 — SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION · recruiting
- NCT05907746 — Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Defici · Phase 2 · active not recruiting
- NCT07406217 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients · Phase 2 · recruiting
- NCT05587894 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Tri · Phase 2 · recruiting
Other CENTOGENE GmbH Rostock trials
Trials by the same sponsor.
- NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
- NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
- NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
- NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
- NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03651245 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
- Last refreshed: 13 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03651245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing